Abstract
Purpose: Skin distances ≤6 mm have been consistently associated with unacceptable toxicity and suboptimal cosmetic outcome with the MammoSite®. However, skin distance only approximates the skin dose. With a single lumen device, the dose will depend not only on skin thickness but also on balloon diameter and dwell position location/weighting. On the currently accruing national phase III trial (RTOG 04-13/NSABP B-39), treatment is considered acceptable if the maximum skin dose is ≤145% of the prescription dose.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
